The OSUCCC Nucleic Acid Shared Resource (NASR) provides services to cancer investigators for DNA sequencing, genotyping, DNA methylation analysis, and quantitative real-time PCR on a variety of instrumentation platforms, as well as access to equipment for nucleic acid purification, quantitative measurement and quality control of nucleic acids, and nucleic acid imaging. NASR services include comprehensive training, consultation and assistance in experimental design and expertise to develop novel methodologies and applications relevant to cancer research. The integration of several technologies into a new multifunctional OSUCCC NASR in 2004 and consolidation of the NASR on the second floor of the Biomedical Research Tower in 2007 promoted interdisciplinary activity, and enhanced cross training of staff increasing their technical skills, motivation and flexibility. These changes resulted in optimal usage of space equipment and expertise, and increased productivity and cost-effectiveness. New equipment for highthroughput gene expression analysis and next-generation sequencing technologies has expanded NASR research capabilities for both genomic and epigenomic support. Highly experienced personnel perform continuous optimization of methods and protocols with outstanding quality control which is crucial for the improvement of data quality and turnaround times. There are strong established interactions with other shared resources including the Microarray, Proteomics and Biomedical Informatics Shared Resources. The NASR maintains a website providing basic information about the policies of the facility and convenient online scheduling and secure data transfer mechanisms. The NASR's specific goals are to: 1) provide reliable, high-quality, affordable, low- and high-throughput, genomic and epigenomic support;2) provide, optimize, develop and apply early access technologies relevant to cancer research;3) provide and develop infrastructure and staff for new technologies for cancer research;4) provide immediate access to data analysis and troubleshooting;5) provide investigators with training in data analysis, experimental strategies and assistance with investigator publications. Last year's total operational expenses of $1,540,977 were covered by 46.8% charge-backs/other grants, 11.1%i CCSG support and 42.1% institutional support. In the past year, 90.9% of NASR usage was from 96 peer-reviewed funded investigators from all 6 OSUCCC research programs. Building on this solid foundation, the mandate of the OSUCCC NASR is to be an outstanding resource, to provide the best support, and to provide the highest-quality data at the lowest price in a period of rapid and profound technological advances.

Public Health Relevance

The NASR provides OSUCCC members efficient, high-quality technical and consultative services for DNA sequencing, genotyping, DNA methylation analysis, and quantitative real-time PCR, using state-of-the-art instrumentation platforms and equipment. The NASR supports proven, standard technologies and new cutting-edge next-generation sequencing and profiling technologies, resulting In high impact scientific cancer relevant accomplishments bolstered by current progress in comparative genomics, biomedical research and the human genome project.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-38
Application #
8601823
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$203,535
Indirect Cost
$70,069
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Pettit, Cory; Webb, Amy; Walston, Steve et al. (2018) MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma. Oncotarget 9:28951-28964
Miller, Eric D; Fisher, James L; Haglund, Karl E et al. (2018) Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiat Oncol 13:196
Fenn, J Daniel; Johnson, Christopher M; Peng, Juan et al. (2018) Kymograph analysis with high temporal resolution reveals new features of neurofilament transport kinetics. Cytoskeleton (Hoboken) 75:22-41
Colombo, Mara; Lòpez-Perolio, Irene; Meeks, Huong D et al. (2018) The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Hum Mutat 39:729-741
Hendricks, William P D; Zismann, Victoria; Sivaprakasam, Karthigayini et al. (2018) Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet 14:e1007589
Gardner, Heather L; Rippy, Sarah B; Bear, Misty D et al. (2018) Phase I/II evaluation of RV1001, a novel PI3K? inhibitor, in spontaneous canine lymphoma. PLoS One 13:e0195357
Barnhouse, Victoria R; Weist, Jessica L; Shukla, Vasudha C et al. (2018) Myoferlin regulates epithelial cancer cell plasticity and migration through autocrine TGF-?1 signaling. Oncotarget 9:19209-19222
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Di Marcantonio, Daniela; Martinez, Esteban; Sidoli, Simone et al. (2018) Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618
Shirts, Brian H; Konnick, Eric Q; Upham, Sarah et al. (2018) Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes. Am J Hum Genet 103:19-29

Showing the most recent 10 out of 2602 publications